How Medical Device Companies Can Thrive in the Next Decade
Share:
The medtech industry is facing a lot of challenges.
From declining R&D productivity and talent shortages to shifting care settings and rising cybersecurity concerns, medical device companies are under immense pressure to stay compliant while driving profitability.
Inspired by insights from the Medtech Pulse: Thriving in the Next Decade report, this article explores these challenges and how BioT’s infrastructure empowers medical device companies to tackle them head-on.
Let’s dive in.
Medical device companies' biggest roadblocks: are you ready to overcome them?
There are a number of key challenges that medical device companies will have to overcome in the coming years:
Limited R&D capacity and talent shortages
Declining R&D productivity and innovation cycles
Shift to alternate care settings (home and virtual care)
Need for AI and digital tools
Cybersecurity and privacy concerns
Pressure to improve profit margins
Let's unpack these challenges.
The triple threat to medical device companies’ growth: R&D, talent shortages, and red tape
According to the report, among the most pressing challenges for medtech companies are limited R&D capacity (25%), talent shortages (23%), and complex regulatory processes (19%). These issues can slow down innovation and increase operational costs:
Key challenges include limited R&D team capacity (25%), talent shortages (23%), and complicated regulatory processes (19%).
Here’s how BioT helps address these constraints:
Reducing Talent Needs: As a PaaS, BioT minimizes the need for companies to maintain large backend engineers, DevOps or DevSecOps teams, streamlining operations and lowering talent costs.
Simplifying Regulatory Compliance: BioT’s IEC 62304-compliant Design History File (DHF) expedites FDA and CE submissions, cutting complexity and time.
Scaling with Ease: By leveraging standard cloud providers, BioT ensures seamless scalability without requiring extensive in-house IT infrastructure.
By addressing these constraints head-on, medical device companies can refocus on innovation and efficiency, paving the way for sustainable growth.
From 196 to 74 FDA approvals: Fixing Medtech’s innovation decline
R&D productivity in medtech is on the decline, with FDA approvals per $1 billion of R&D spending dropping sharply- from 196 in 2011 to just 74 in 2022.
A sharp decline in FDA approvals per $1 billion of R&D spending, from 196 in 2011 to 74 in 2022.
There’s clearly a need for tools that accelerate innovation without compromising quality.
BioT provides several solutions to combat this challenge:
SaMD Studio: BioT’s software-as-a-medical-device (SaMD) studio provides a structured environment for companies to rapidly develop, test, and deploy applications, accelerating the innovation cycle.
Out-of-the-Box Modules: Pre-built modules for therapy management, device diagnostics, and adherence tracking allow companies to launch solutions faster without reinventing the wheel.
Time-to-Market Advantage: Cloud-native solutions can be operational in as little as one day, bypassing months of backend development efforts.
With solutions like BioT’s infrastructure, medical device companies can reverse this downward trend, accelerating innovation without compromising quality or compliance.
Shifting to alternate care settings: meeting patients where they are
The landscape of healthcare is shifting.
Alternate care settings like home care and virtual care are expanding rapidly, reshaping the way medical services are delivered.
These settings are projected to increase their share of the U.S. healthcare provider profit pool from 4% in 2017 to 5% in 2027, while general acute care facilities’ share is expected to decline from 42% to 38%.
This trend signals a growing need for medical devices to be optimized for remote use and telehealth integration.
How BioT supports this shift:
Remote Monitoring: BioT powers real-time patient monitoring for devices like glucose monitors and cardiac care systems, enabling care delivery in patients’ homes.
Telehealth Integration: Secure live video consultations and adherence tracking to improve patient engagement and outcomes in remote settings.
Personalized Care: BioT’s platform supports tailored therapy management by collecting real-time adherence and biomarker data.
The rise of alternate care settings is an opportunity for medical device companies to innovate solutions that meet patients where they are, improving access and outcomes.
Leveraging AI and digital tools for smarter solutions
As industries adopt advanced digital tools, medical device companies are forced to do the same to remain competitive.
Technologies like AI, advanced analytics, and interoperable data systems are demonstrating the ability to cut product development cycles by 50% and reduce costs by 30% in other sectors.
A three-layer ecosystem of medical devices - Engagement Layer for user interaction, Intelligence Layer for actionable insights via analytics, and Infrastructure Layer as the data backbone - working together to optimize functionality, innovation, and care delivery.
How BioT empowers innovation with AI
AI Training and Validation: BioT empowers companies to utilize the Intelligence Layer, enabling companies to train and validate AI models on collected patient data. This leads to smarter, more accurate insights and enhanced patient outcomes.
Streamlined Development: By leveraging the Infrastructure Layer, including secure cloud platforms and interoperable data systems, BioT reduces backend complexity. This enables Medical Device Companies to focus on developing innovative Engagement Layer solutions like patient apps and diagnostic tools, accelerating time-to-market.
By connecting the Engagement, Intelligence, and Infrastructure Layers, BioT ensures a seamless ecosystem for faster innovation and better patient outcomes
AI is reshaping the medtech industry.
BioT ensures medical device companies can embrace these advancements with ease.
Enhancing cybersecurity and privacy
Cybersecurity and privacy are critical, with Medical Device Companies increasingly targeted due to sensitive patient data. Operating margins and profitability are under scrutiny as well.
How BioT Assists:
Built-In Security: Advanced measures such as encryption, regular vulnerability scans, and certifications like ISO 27001, SOC 2, and HITRUST ensure robust data protection.
Regulatory Adherence: BioT meets stringent global privacy and security standards, reducing the regulatory burden for Medical Device Companies.
With cybersecurity threats on the rise, BioT’s comprehensive solutions ensure medical device companies can protect their data (and their reputation).
Boosting profit margins through efficiency
A 200 - 400 basis point decline in Medtech margins since 2021
As the correlation between profit margins and company valuations has more than doubled since 2016, Medical Device Companies face increasing pressure to sustain profitability. This challenge is further amplified by a decline in MedTech margins of 200 - 400 basis points since 2021, driving the need for improved operational efficiency and cost optimization to maintain competitiveness and investor confidence.
How BioT drives profitability
Lower Operational Costs: BioT’s PaaS model reduces OPEX by handling cloud infrastructure and compliance needs, freeing resources for innovation.
Flexibility for Iteration: The platform’s no-code/low-code flexibility makes it extremely easy to re-iterate and re-launch solutions, enabling cost-efficient product evolution.
Revenue Generation: By enabling SaaS business models, BioT supports new revenue streams for Medical Device Companies through subscription services.
The path forward for medical device companies
The Medtech Pulse report is a wake-up call for medical device companies to innovate and adapt now.
With challenges mounting, the path to success lies in adopting scalable, secure, and flexible solutions.
BioT’s infrastructure empowers medical device companies to:
